With an expiration date still more than a year away, here's what the latest details reveal.

In a significant move to mitigate the ongoing shortage of ADHD medications in the U.S., the Drug Enforcement Administration (DEA) has authorized a substantial increase in the production limits for ...

To address the nationwide shortage of medications for attention-deficit/hyperactivity disorder, the Drug Enforcement Administration is allowing an increase in the ...

A stimulant drug used to treat ADHD has become the fastest-growing script on the Pharmaceutical Benefits Scheme, prompting ...

The U.S. Drug Enforcement Administration (DEA) has allowed an increase in Vyvanse production of around 24 percent to help with the ADHD drug shortage nationwide. The DEA greenlighted the spike in ...

Less than four months after Teva’s Adderall was erased from the FDA shortage list, supply problems with another attention-deficit/hyperactivity disorder (ADHD ...

WASHINGTON — The Drug Enforcement Administration has increased the production limit for the ADHD drug Vyvanse and its generic versions to combat the medicine's ongoing shortage, according to a notice ...

Shire and New River Pharmaceuticals have received FDA approval to market Vyvanse (lisdexamfetamine dimesylate), for the treatment of attention deficit hyperactivity disorder (ADHD). Vyvanse is a ...

LONDON, June 28 (Reuters) - Britain's Shire Plc is challenging its sales force to capture 50 percent of the U.S. market for treating attention deficit hyperactivity disorder (ADHD) by early next ...